A new drug cleared 91% of brain amyloid plaques in 7 months, showing faster results than current Alzheimer's treatments and advancing to Phase III trials in 2025.

Cognito’s OVERTURE trial demonstrated significant ‘time saved’ in functional and cognitive decline at both six and 18 months.

Sleep and brain experts respond to new findings on the association between REM sleep and Alzheimer's disease, recommending ...

Troculeucel, a cryopreserved autologous, non-genetically modified NK cell product, appears to cross the blood brain barrier (BBB) via CXCR3, to reduce neuroinflammation via a simple IV administration.

In a Phase Ib/IIa trial, 91% of patients receiving the highest dose of trontinemab were amyloid negative after seven months of treatment, representing what B. Riley Securities called a “paradigm shift ...

A tiny flower-shaped particle could help to pave the way for a new treatment approach to Alzheimer's and Parkinson's that targets the root causes.

In the context of Alzheimer's disease, higher levels of RTP801 can inhibit this complex and cause problems in RNA splicing and subsequent production of relevant proteins, such as brain-derived ...

Why is this mechanism crucial for neuronal health? The study describes how the RTP801 factor negatively regulates the activity of the tRNA ligase complex (tRNA-LC), which is critical for ...

Provided by Business WireJun 18, 2025, 11:36:00 AM Publication in Alzheimer’s & Dementia Elucidates Multimodal Mechanism of Action Underpinning Promising New Neuromodulation Therapy for ...

Key findings Dark microglia and Alzheimer's disease: Using electron microscopy, the researchers identified an accumulation of "dark microglia," a subset of microglia associated with cellular ...

Researchers at the University of California, Irvine, have developed a groundbreaking therapy for Alzheimer’s disease by using stem cells to program human immune cells for targeted treatment.